Lee, Yoon-Suk et al. published their patent in 2022 |CAS: 62640-03-3

The Article related to benzenesulfonamide fused heteroaryl preparation nitrogen oxide donating pde5 pde6, eye disease glaucoma diabetic retinopathy benzenesulfonamide fused heteroaryl preparation, age related macular degeneration amd benzenesulfonamide fused heteroaryl preparation and other aspects.Computed Properties of 62640-03-3

On May 12, 2022, Lee, Yoon-Suk; Kim, Kyung-Sun; Kim, Jeong-Ah; Moon, An-Na; Song, Dong-Keun; Jung, Ju-Young published a patent.Computed Properties of 62640-03-3 The title of the patent was Preparation of benzenesulfonamides linked to a fused heteroaryl as nitrogen oxide-donating PDE-5 and/or PDE-6 inhibitors. And the patent contained the following:

The title compounds I [X1 and X2 = (independently) N and C, and at least one of X1 and X2 = N; R1 = H, (un)substituted alkyl; R2 =(un)substituted alkyl; R3 = (un)substituted alkoxy; R4 = H or (un)substituted alkyl, and R5 = (un)substituted 4-membered carbocycle or heterocycle; or R4 and R5 together with the nitrogen atom to which they are attached are cyclically linked to form (un)substituted 4-membered heterocycle] or pharmaceutically acceptable salts, solvates, hydrates, prodrugs, or stereoisomers thereof, useful for treating a variety of eye diseases, were prepared For example, reacting 4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)benzenesulfonyl chloride with azetidin-3-ol hydrochloride afforded 92% II. Said compounds I are nitrogen oxide (NO) donating PDE-5 and/or -6 inhibitor compounds that include a nitrogen oxide-containing donor substituent attached to a benzenesulfonamide group. The compounds I can provide dual functionality for increasing protein kinase G (PKG) activity by inhibiting PDE-5 and PDE-6, and/or stimulating guanylate cyclase via donation of NO from the donor substituent of the compound (data given for representative compounds I). The present disclosure also provides methods of using said compounds I and compositions for inhibiting PDE-5 and/or -6 and increasing activity of PKG. Compounds I may be used as a therapeutic agent for glaucoma, age-related macular degeneration, diabetic retinopathy, xerophthalmia, dry eye syndrome, cataracts or uveitis. Ophthalmic composition comprising the compound I was disclosed. The experimental process involved the reaction of 2-(Methylamino)ethan-1-ol hydrochloride(cas: 62640-03-3).Computed Properties of 62640-03-3

The Article related to benzenesulfonamide fused heteroaryl preparation nitrogen oxide donating pde5 pde6, eye disease glaucoma diabetic retinopathy benzenesulfonamide fused heteroaryl preparation, age related macular degeneration amd benzenesulfonamide fused heteroaryl preparation and other aspects.Computed Properties of 62640-03-3

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts